4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
7.810 USD   +5.97%
05/13SVB Securities Adjusts 4D Molecular Therapeutics' Price Target to $28 from $30, Keeps Outperform Rating
MT
05/124D MOLECULAR THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
05/124D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-150, A Dual-Transgene Intravitreal Gene Therapy for Patients with Wet AMD

01/06/2022 | 04:03pm EDT

4D Molecular Therapeutics, Inc. announced that the first patient has been dosed in the Phase 1/2 clinical trial of 4D-150 for neovascular age-related macular degeneration (wet AMD). The Phase 1/2 clinical trial is a dose-escalation and randomized, controlled, masked expansion trial of intravitreal 4D-150 and is expected to enroll approximately 60 adults with wet AMD. In the dose-escalation phase, multiple dose levels of 4D-150 will be examined in an open-label, 3+3 design with an initial dose of 3E10 vg/eye. In dose expansion, patients (n=50) will be randomized 2:2:1 to receive one of 2 dose levels of 4D-150 (n=20 for each dose level) or aflibercept (n=10). The primary endpoints of the study are safety and tolerability. Secondary endpoints include the number of supplemental aflibercept injections received and change from baseline in best corrected visual acuity (BCVA) over time.


© S&P Capital IQ 2022
All news about 4D MOLECULAR THERAPEUTICS, INC.
05/13SVB Securities Adjusts 4D Molecular Therapeutics' Price Target to $28 from $30, Keeps O..
MT
05/124D MOLECULAR THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condi..
AQ
05/124D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended Ma..
CI
05/12Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS Posts Q1 Revenue $1.2M
MT
05/124D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Cor..
GL
05/124D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Cor..
AQ
05/10TRANSCRIPT : 4D Molecular Therapeutics, Inc. Presents at Bank of America 2022 Healthcare C..
CI
05/054D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Confere..
GL
05/054D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Confere..
AQ
04/044D Molecular Therapeutics Starts Cystic Fibrosis Trial with Dosing of First Patient
MT
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 15,0 M - -
Net income 2022 -84,7 M - -
Net cash 2022 47,1 M - -
P/E ratio 2022 -2,59x
Yield 2022 -
Capitalization 252 M 252 M -
EV / Sales 2022 13,7x
EV / Sales 2023 18,5x
Nbr of Employees 137
Free-Float 88,3%
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 7,81 $
Average target price 28,25 $
Spread / Average Target 262%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Melissa Kotterman Vice President-Discovery & Engineering
Fred Kamal Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-64.40%252
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567